Articles By Anuja Singh
RecovryAI’s FDA Breakthrough: Post-Op AI Agents’ 85% Complication Prediction or Wearable Hype Meets Reality?
RecovryAI snared FDA Breakthrough Device Designation on March 4, 2026, for its physician-prescribed Virtual Care Assistants—AI agents that…
ByArdent Health’s Hellocare.ai Virtual Nursing Play: 20% Readmission Slash or AI Overreach in Care?
Ardent Health’s March 3-4, 2026, partnership with Hellocare.ai deploys AI modules for virtual nursing, telehealth, and real-time patient…
VA’s Nationwide Ambient AI Scribe Rollout: Burnout Buster or Documentation Digitized Trap?
The U.S. Department of Veterans Affairs on March 4, 2026, greenlit ambient scribe AI from Knowtex and Abridge…
Gilead’s $8B Arcellx CAR-T Swoop & Lilly Zepbound Triumph: Obesity/CAR-T Mania or Bubble Burst…
Gilead’s March 2026 $8B acquisition of Arcellx—securing CAR-T anito-cel for multiple myeloma with 73% ORR Phase 1b data—and…
FDA’s AZ/GSK Biologics Rejections: Data Integrity Wake-Up or R&D Overhaul Catalyst?
FDA rejection letters issued March 3-4, 2026, flagged data integrity lapses in AstraZeneca’s subcutaneous tezepelumab (asthma) and GSK’s…
Acadia’s Daybue CHMP Fight: $2B Rett Revenue at Stake or EMA Brick Wall?
Acadia Pharmaceuticals on March 3, 2026, fired back at CHMP’s rejection of Daybue (trofinetide) expansion into granular symptom…
RecovryAI’s FDA Breakthrough: Post-Op AI Agents’ 85% Complication Prediction or Wearable Hype Meets Reality?
RecovryAI snared FDA Breakthrough Device Designation on March 4, 2026, for its physician-prescribed Virtual Care Assistants—AI agents that…
Ardent Health’s Hellocare.ai Virtual Nursing Play: 20% Readmission Slash or AI Overreach in Care?
Ardent Health’s March 3-4, 2026, partnership with Hellocare.ai deploys AI modules for virtual nursing, telehealth, and real-time patient…
VA’s Nationwide Ambient AI Scribe Rollout: Burnout Buster or Documentation Digitized Trap?
The U.S. Department of Veterans Affairs on March 4, 2026, greenlit ambient scribe AI from Knowtex and Abridge…
Gilead’s $8B Arcellx CAR-T Swoop & Lilly Zepbound Triumph: Obesity/CAR-T Mania or Bubble Burst…
Gilead’s March 2026 $8B acquisition of Arcellx—securing CAR-T anito-cel for multiple myeloma with 73% ORR Phase 1b data—and…
FDA’s AZ/GSK Biologics Rejections: Data Integrity Wake-Up or R&D Overhaul Catalyst?
FDA rejection letters issued March 3-4, 2026, flagged data integrity lapses in AstraZeneca’s subcutaneous tezepelumab (asthma) and GSK’s…
Acadia’s Daybue CHMP Fight: $2B Rett Revenue at Stake or EMA Brick Wall?
Acadia Pharmaceuticals on March 3, 2026, fired back at CHMP’s rejection of Daybue (trofinetide) expansion into granular symptom…